1) Kasahara-Kiritani M, et al.: Understanding anhedonia in major depressive disorder in Japan: epidemiology and unmet needs from patients’ and physicians’ perspectives. BMC Psychiatry, 25: 631, 2025.
2) Geugies H, et al.: Impaired reward-related learning signals in remitted unmedicated patients with recurrent depression. Brain, 142: 2510-2522, 2019.
3) Phillips RD, et al.: Striatal dopamine in anhedonia: A simultaneous [(11)C]raclopride positron emission tomography and functional magnetic resonance imaging investigation. Psychiatry Res Neuroimaging, 333: 111660, 2023.
4) Vaccarino SR, et al. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder. BJPsych Open, 10: e18, 2024.
5) Liemburg E, et al.: An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry, 44: 109-13, 2011.
6) Watanabe K, et al.: Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. Neuropsychiatr Dis Treat, 18:363-373, 2022.
7) Serretti A. et al.: Anhedonia: Current and future treatments, 4: e70088, 2025.